Our Team
Engineered for drug discovery innovation. Our multidisciplinary team unites scientists, platform developers, and commercial strategists to deploy agentic orchestration, physics-informed molecular science, and specialised computational services that turn complex questions into defensible next actions.
Antonio Benedetti
Executive Chairman
Vid Stojevic, PhD
CEO, Co-founder
David Wright, PhD
CTO, Co-founder
Parminder Ruprah, PhD
Head of Chemistry, Co-founder
Jarryl D’Oyley, PhD
Project Manager, Co-founder
Georg Schusteritsch, PhD
Senior Quantum Scientist
Will Gerrard, PhD
Platform Development Team Lead
Fabian Byléhn, PhD
Computational Drug Design
Doug Best
Business Development Lead
Elise White, PhD
Computational Drug Design
Our Advisors
We are supported by an expert team of advisors that are working closely with us on corporate and business development, as well as, ongoing scientific development of our proprietary modelling and AI technology.
Prof. George Booth
Physics Professor
Kings College London
Prof. Adrian Mulholland
Head of Physical and Theoretical Chemistry
University of Bristol
Prof. John Bridgewater
Clinical Professor
UCL
Jarvist Moore-Frost, PhD
Royal Society Research Fellow
Imperial College London
Prof. Andrew Green
Chair of Condensed Matter Physics
UCL
Alessandra Cesano, PhD
Seasoned senior executive
Board Member at Summit Therapeutics
David Barrett, PhD
Seasoned Pharma Executive
Astellas Engineered Small Molecules UK
Board of Directors
Antonio Benedetti
Executive Chairman
Andy Mulvaney
Non-Exec Director
Vjeko Jadresic
Non-Exec Director
Vid Stojevic
CEO
Sunil Shah
Non-Exec Director
Ted Witek
Board Member
Robert Hornby
Board Observer
David Wright
CTO
Our Partners
We are currently backed by a series of seed round investors, grants and academic partners.
